Contact
THE SCIENCE
OF EARLIER
Transforming the early detection
and intervention of cancer
Our Unique Biomarker
Technology
OncAlert Labs develops tests based on patented technology that detects specific protein markers known to indicate an elevated risk for early stage cancers, even prior to observation of visual or physical symptoms.
Actionable Insights for Earlier Oral Cancer
Detection
OraMark’s oral rinse collection method is easy to administer and non-invasive for the patient. The test delivers accurate, quantitative results that help optimize patient management and surveillance both pre- and post-biopsy.
Featured News and Events
March 22, 2017 |
Vigilant Biosciences Announces Multiple Poster Presentations in Support of OncAlert® Oral Cancer and OncAlert Labs Product Lines
Vigilant Biosciences, Inc. today announced the acceptance of five abstracts regarding data related to studies conducted by the Company to better understand the performance characteristics of a combined salivary CD44 and total protein assay as an aid in the diagnosis of head and neck squamous cell carcinoma (HNSCC).The studies, along with others, helped provide direction for […]
March 20, 2017 |
Vigilant Biosciences to Showcase OncAlert® Oral Cancer Product Line at International Dental Show 2017
Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, will showcase its OncAlert® Oral Cancer product line in Hall 5.1, Stand: D069 at the 37th International Dental Show (IDS), the world’s leading tradeshow for the dental industry, being held March 21-25, 2017 in Cologne, […]
March 15, 2017 |
Vigilant Biosciences Announces Poster Presentation on Multivariate Oral Rinse Models for Prediction of Head and Neck Squamous Cell Carcinoma at the 6th International Conference on Innovative Approaches in Head and Neck Oncology
Matthew H.J. Kim, Founder, Chairman and CEO at Vigilant Biosciences, will present a poster on the study, “Multivariate oral rinse models predict Head and Neck squamous cell carcinoma (HNSCC),” at the 6th International Conference on Innovative Approaches in Head and Neck Oncology (ICHNO), from March 16-18, 2017, in Barcelona, Spain.